GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
O

Ocean Biomedical OCEA · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

0.00%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Ocean Biomedical

From its filings with the US Securities and Exchange Commission

SEC filings

Ocean Biomedical is based in New York, New York and is incorporated in Delaware. Its shares trade on OTC under the ticker OCEA. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2024, it reported a net loss of $9.5m. At that date it held total assets of $902,000 and shareholders' equity of −$97.6m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
15 Sept 2021
Employees
9
Head office
515 MADISON AVE SUITE 8078, NEW YORK, NY, 10022
Incorporated in
DE
Classification
Pharmaceutical Preparations
Filer status
<br>Emerging growth company

Leadership

Pay as last reported

  • Dr. Chirinjeev KathuriaExecutive Chairman of the Board, Founder, since 2023
  • Dr. Jonathan KurtisDirector
  • Ms. Elizabeth NgDirector, since 2023

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
29
Environment
30
Social
40
Governance
17
Carbon reduction policy
No
Human rights policy
No

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Ocean Biomedical Inc develops therapeutic products in oncology and fibrosis.
  • The firm accelerates commercialization of assets from research universities.
  • Three malaria product candidates target specific parasite antigens effectively.

Weaknesses

  • The company has only nine employees currently on staff.
  • Operations are concentrated in New York City, US.
  • The firm went public on 15 September 2021 recently.

Opportunities

  • Developing humanized monoclonal antibodies for non-small cell lung cancer.
  • Creating treatments for glioblastoma multiforme using novel targets.
  • Advancing malaria vaccines targeting PfSEA-1 and PfGARP antigens.

Threats

  • Competing in the crowded biotechnology sector globally.
  • Regulatory hurdles for new infectious disease treatments.
  • High costs associated with clinical development phases.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.